AR098615A1 - Péptido para el tratamiento de hipoglicemia severa - Google Patents

Péptido para el tratamiento de hipoglicemia severa

Info

Publication number
AR098615A1
AR098615A1 ARP140104513A ARP140104513A AR098615A1 AR 098615 A1 AR098615 A1 AR 098615A1 AR P140104513 A ARP140104513 A AR P140104513A AR P140104513 A ARP140104513 A AR P140104513A AR 098615 A1 AR098615 A1 AR 098615A1
Authority
AR
Argentina
Prior art keywords
lys
ser
treatment
peptide
tyr
Prior art date
Application number
ARP140104513A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR098615A1 publication Critical patent/AR098615A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a un péptido útil en el tratamiento de hipoglicemia. Reivindicación 1: Un compuesto caracterizado porque comprende la secuencia de aminoácido de Tyr-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-(Aib)-Lys-Lys-Ala-Gln-Glu-Phe-Val-Glu-Trp-Leu-Leu-Lys-Thr-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Lys-Ser-Lys-NH₂ (SEC ID Nº 2).
ARP140104513A 2013-12-18 2014-12-04 Péptido para el tratamiento de hipoglicemia severa AR098615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917716P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
AR098615A1 true AR098615A1 (es) 2016-06-01

Family

ID=52273565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104513A AR098615A1 (es) 2013-12-18 2014-12-04 Péptido para el tratamiento de hipoglicemia severa

Country Status (22)

Country Link
US (1) US20160311882A1 (es)
EP (1) EP3083667A1 (es)
KR (1) KR20160075826A (es)
CN (1) CN105829340A (es)
AP (1) AP2016009267A0 (es)
AR (1) AR098615A1 (es)
AU (1) AU2014366425B2 (es)
BR (1) BR112016010635A2 (es)
CA (1) CA2930596A1 (es)
CR (1) CR20160227A (es)
DO (1) DOP2016000142A (es)
EA (1) EA201690966A1 (es)
HK (1) HK1224305A1 (es)
IL (1) IL245491A0 (es)
MA (1) MA39110B1 (es)
MX (1) MX2016007988A (es)
PE (1) PE20160847A1 (es)
PH (1) PH12016501183A1 (es)
SG (1) SG11201604237PA (es)
TN (1) TN2016000208A1 (es)
TW (1) TW201609128A (es)
WO (1) WO2015094876A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN113396156A (zh) 2019-02-05 2021-09-14 伊莱利利公司 胰高血糖素类似物激动剂及其使用方法
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
MX2010012695A (es) * 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2718318T3 (en) * 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
JP6396211B2 (ja) * 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果

Also Published As

Publication number Publication date
BR112016010635A2 (pt) 2017-12-05
AP2016009267A0 (en) 2016-06-30
PH12016501183A1 (en) 2016-07-25
US20160311882A1 (en) 2016-10-27
CA2930596A1 (en) 2015-06-25
PE20160847A1 (es) 2016-09-10
AU2014366425B2 (en) 2016-12-08
CR20160227A (es) 2016-07-12
HK1224305A1 (zh) 2017-08-18
WO2015094876A1 (en) 2015-06-25
EP3083667A1 (en) 2016-10-26
KR20160075826A (ko) 2016-06-29
AU2014366425A1 (en) 2016-05-26
TN2016000208A1 (en) 2017-10-06
CN105829340A (zh) 2016-08-03
EA201690966A1 (ru) 2016-12-30
MX2016007988A (es) 2016-09-09
TW201609128A (zh) 2016-03-16
DOP2016000142A (es) 2016-07-15
MA39110A1 (fr) 2017-09-29
IL245491A0 (en) 2016-06-30
SG11201604237PA (en) 2016-07-28
MA39110B1 (fr) 2018-04-30

Similar Documents

Publication Publication Date Title
CL2016001405A1 (es) A peptide mixture
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CU20160060A7 (es) Péptidos, ácidos nucleicos y células, útiles en la inmunoterapia personalizada contra diversos tumores cerebrales y neuronales
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
AR098615A1 (es) Péptido para el tratamiento de hipoglicemia severa
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CO2019006443A2 (es) Peptido para tratar degeneracion macular relacionada con la edad
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
SG10201805039UA (en) Protease resistant peptides
AR098616A1 (es) Péptido para el tratamiento de hipoglicemia severa
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
AR083766A1 (es) Peptido inmunogenico
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
GT201600117A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ES2526109R2 (es) Péptido y composición farmacéutica para el tratamiento del cáncer
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
IN2014MN01376A (es)
BR112016007816A2 (pt) composições peptídicas inovadoras
ES2545458T3 (es) Fragmentos de PTEC
MX2020005454A (es) Tratamiento de cancer mejorado.
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Legal Events

Date Code Title Description
FB Suspension of granting procedure